However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But ...

A major new meta-analysis from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has ...

SaveHealth explores the historical trajectory of weight loss drugs, examining their scientific basis, regulatory battles, ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity Medicine 2025.The use of GLP-1 receptor agonists and other weight-loss medications ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...